Critical Pharmacodynamic Warning

copanlisib weakly inhibits the 3A457 metabolic pathway.

When patients take copanlisib concurrently with drugs metabolized by 3A457, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.

Clinical Impact: As a weak inhibitor, copanlisib can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.

Clinical Overview for copanlisib

This page outlines known interaction pathways involving copanlisib, focusing primarily on its profile as a Weak inhibitor affecting the 3A457 pathway.

Enzyme Interaction Profile

copanlisib demonstrates weak inhibitor potency against 3A457. This level of inhibition causes ≥1.25-fold but <2-fold increase in AUC of substrate drugs.

Inhibitor

A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.

Clinical Example: copanlisib weakly inhibits 3A457

Inducer

A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.

Interaction Details
Drug Name copanlisib
Affected Enzyme 3A457
Inhibitor Strength Weak inhibitor Low Severity
Inducers No inducers listed
Inhibitors omeprazole
Clinical Recommendations

Generally safe for co-administration. Routine monitoring recommended.

Monitoring Parameters:
  • Therapeutic drug levels
  • Adverse effect monitoring
  • Clinical response assessment
Dose Considerations:
  • Consider dose reduction
  • Evaluate alternative therapies
  • Adjust based on response
Quick Facts
Interaction ID
9239
Primary Pathway
3A457
Interaction Type
Enzyme Inhibition
Clinical Phase
Low Severity
Clinical Significance

Minor clinical significance. Routine monitoring sufficient.

Information Sources
  • FDA Drug Interaction Database
  • Clinical Pharmacology Guidelines
  • Pharmaceutical Labeling Information
  • Published Clinical Studies
Last updated: June 15, 2026
Back Return to Database